EP2563364A1 - Combinaison de carmotérol et de fluticasone utilisée pour le traitement de maladies respiratoires - Google Patents

Combinaison de carmotérol et de fluticasone utilisée pour le traitement de maladies respiratoires

Info

Publication number
EP2563364A1
EP2563364A1 EP11720621A EP11720621A EP2563364A1 EP 2563364 A1 EP2563364 A1 EP 2563364A1 EP 11720621 A EP11720621 A EP 11720621A EP 11720621 A EP11720621 A EP 11720621A EP 2563364 A1 EP2563364 A1 EP 2563364A1
Authority
EP
European Patent Office
Prior art keywords
composition according
pharmaceutically acceptable
medicament
carmoterol
medicament composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11720621A
Other languages
German (de)
English (en)
Inventor
Mahmut Bilgic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP2563364A1 publication Critical patent/EP2563364A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Definitions

  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising the active agents carmoterol and fluticasone and/or pharmaceutically acceptable derivatives thereof so as to be used in the treatment of respiratory diseases, especially in asthma and chronic obstructive pulmonary disease (COPD), and the delivery of this composition.
  • COPD chronic obstructive pulmonary disease
  • bronchia are the channels which function to distribute the inhaled air into the lung tissues.
  • stimulants such as allergen, infection, good and bad smell, smoke cause contractions in the airway muscles (bronchoconstriction) and/or excessive secretion in glands and results in contractions in the airways.
  • bronchoconstriction a chronic obstructive pulmonary disease
  • ⁇ 2- agonists induce an alleviating or eliminating effect on bronchoconstriction in the treatment of respiratory diseases such as asthma and COPD.
  • Carmoterol (Formula 1), which has the chemical name 8 -hydroxy- 5 -[( 1 R)- 1 -hydroxy-2-[[(2R)- 1 -(4-methoxyphenyl)prophane-2- yl] amino] ethyl]- lH-quinolin-2-one, is a ⁇ 2- agonist that was first disclosed in the patent numbered EP0147719.
  • Fluticasone is a corticosteroid named S-(fluoromethyl)-6a,9-difluoro-l i ,17-dihydroxy-16a- methyl-3-oxoandrosta-l,4-dien-17-carbothionate. Fluticasone, which is a potent antiinflammatory drug, was first described in the patent numbered US4335121.
  • ⁇ 2- agonist and a corticosteroid in the treatment of respiratory diseases such as asthma and COPD in is known the prior art.
  • the treatment comprising these drugs may not achieve sufficient reliability in some patients.
  • these drugs should be taken twice or more a day because they do not have long duration of action.
  • the adaptation of patients to the treatment decreases as a result of this frequent dose intake.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising the active agents carmoterol or a pharmaceutically acceptable derivative thereof and fluticasone and/or a pharmaceutically acceptable derivative thereof as combined in order to be used in the treatment of respiratory diseases such as asthma, COPD and allergic rhinitis.
  • the inventor has surprisingly found that a significant unexpected therapeutic benefit, particularly a synergistic effect, in the treatment of inflammatory or obstructive airways diseases, is obtained by combination therapy using carmoterol and fluticasone and/or a pharmaceutically acceptable derivative thereof.
  • the pharmaceutical composition comprising carmoterol and fluticasone and/or a pharmaceutically acceptable derivative thereof provides faster onset and has a more long-lasting and efficient therapeutic effect when compared with the pharmaceutical compositions containing only one of these active agents.
  • the present invention provides a treatment method in which the medicament composition comprising carmoterol and fluticasone and/or pharmaceutically acceptable derivatives thereof is used as a symptomatolytic medicament.
  • Carmoterol has a short onset of action when taken at particular dose amounts. Therefore, this composition can be used as a symptomatolytic medicament.
  • the present invention provides a medicament in which carmoterol and fluticasone and/or pharmaceutically acceptable derivatives thereof are reciprocally affected in a positive way. Accordingly, carmoterol enhances the anti-inflammatory effect resulting from fluticasone's attaching with glucocorticoid receptors since carmoterol strengthens the translocation of these receptors. Fluticasone, on the other hand, increases the transcription of ⁇ 2 - receptors with which carmoterol attaches.
  • carmoterol and fluticasone and/or pharmaceutically acceptable derivatives thereof induce therapeutic effect at lower doses when they are used as combined compared with their use alone.
  • side effects that the active agents may cause are minimized with the help of lower dose use.
  • the present invention provides a simplified treatment realized by delivery of the medicament comprising carmoterol which is an ultra long-acting ⁇ 2- agonist and fluticasone which is a corticosteroid inducing anti-inflammatory effect and/or pharmaceutically acceptable derivatives thereof once a day.
  • the active agents of the present invention provide a more long-lasting effect, a more effective, treatment and, as a result, a simpler treatment with less frequent dose delivery is provided and patient compatibility is increased.
  • the medicament comprising carmoterol and fluticasone and/or pharmaceutically acceptable derivatives thereof is administered by the inhalation route.
  • the medicament taken by the inhalation route is transmitted to the target area faster compared with the oral and the parenteral route. Thus, it provides faster and more efficient relief to the patient.
  • the present invention enables less frequent dose intake of the medicament comprising carmoterol and fluticasone and/or pharmaceutically acceptable derivatives thereof by the inhalation route compared with the oral and the parenteral route and thus, severity of the side effects that the active agent may cause is minimized.
  • the present invention provides the medicament comprising carmoterol and fluticasone and/or pharmaceutically acceptable derivatives thereof is provided for simultaneous, sequential or separate administration by the inhalation route in the treatment of inflammatory or obstructive airways diseases.
  • the present invention provides a medicament composition in which carmoterol and fluticasone and or pharmaceutically acceptable derivatives thereof are preferably formulated in the same dosage form. Having the active agents in the same dosage form provides a more effective, simpler and cost-effective treatment. Additionally, it is simpler to track the progress of the patient in the treatments utilizing single dosage forms.
  • the medicament comprising carmoterol and fluticasone and/or pharmaceutically acceptable derivatives thereof is delivered via single dose or multi dose inhalation devices.
  • the active agents of the present invention can be inhaled from different devices while all of the active agents of the present invention can also be delivered by a single device. However, delivering the active agents as combined by a single device is preferred according to the present invention.
  • the medicament comprising carmoterol and fluticasone and/or pharmaceutically acceptable derivatives thereof is delivered in aerosol, dry powder, solution or suspension form.
  • the active agents in the medicament of the present invention can be delivered in the same dosage form as well as in different dosage forms. Preferably, all of the active agents of the medicament are delivered in same dosage form.
  • aerosol refers to dispersion or suspension of a liquid, a solution or a solid substance in the air or in a gas.
  • the medicament comprising carmoterol and fluticasone and/or pharmaceutically acceptable derivatives thereof can be inhaled in aerosol form via a suitable device.
  • the aerosol composition that is contained in the device can be characterized by comprising a propellant gas or not.
  • the active agents of the present invention can be inhaled in the same aerosol composition as well as in different aerosol compositions. According to the present invention, the active agents of the present invention are preferably inhaled in the same aerosol composition.
  • the medicament comprising carmoterol and fluticasone and/or pharmaceutically acceptable derivatives thereof can contain propellant gas in addition to the active agents.
  • the medicament comprising propellant gas can be delivered by a pressured metered dose inhaler. These propellant gases are targeted to deliver the active agents to the lungs more easily.
  • the propellant gases are preferably hydrocarbons and halohydrocarbons. Only one of these hydrocarbons or a mixture of them can be used.
  • the particularly used propellant gases are HFA134a, HFA227 or mixture thereof; TGI 34a, TG227 or halogenated alkane derivatives selected from mixtures thereof.
  • the medicament comprising carmoterol and fluticasone and/or pharmaceutically acceptable derivatives thereof can be transmitted to the lungs in a propellant-free aerosol composition by an appropriate inhalation device such as nebulizers.
  • the medicament comprising carmoterol and fluticasone and/or pharmaceutically acceptable derivatives thereof can also comprise co-solvents, stabilizers, surfactants, antioxidants, lubricants and pH-adjusters in addition to the active agents.
  • the medicament delivered in aerosol form and comprising carmoterol and fluticasone and/or pharmaceutically acceptable derivatives thereof can comprise active agent in the range of 0,001% to 8%, preferably in the range of 0,001% to 5% by weight.
  • the medicament comprising carmoterol and fluticasone and/or pharmaceutically acceptable derivatives thereof can be delivered to the patient as a propellant-free solution or an inhalation composition in suspension form by a nebulizer.
  • All of the active agents of the present invention can be inhaled in a single propellant-free solution or suspension together as well as in separate propellant gas-free solutions or suspensions one by one.
  • Water or water-alcohol mixture can be used as solvent in these inhalation formulations.
  • the rate of ethanol to water is at most 80%, preferably 60% by volume in the case that water- alcohol mixture is used.
  • the pH value of suspensions or solutions comprising carmoterol and fluticasone and/or pharmaceutically acceptable derivatives thereof can be in the range of 2 to 7, preferably in the range of 2 to 5.
  • organic or inorganic acids preferably hydrochloric acid, citric acid, ascorbic acid, formic acid, fumaric acid, tartaric acid, malic acid, sulphuric acid or a mixture of one or several of them can be used as a pH-adjuster.
  • the propellant-free inhalation formulations in solution or suspension form may contain edetic acid (EDTA) or salts thereof, excipients, sodium edetate, stabilizer or complexing agents in addition to said substances.
  • EDTA edetic acid
  • the amount of sodium edetate comprised in said solution or suspension can be in the range of 0 mg/100 ml to 120 mg/100 ml, preferably in the range of 0 mg/100 ml to 50 mg/100 ml, more preferably in the range of 0 mg/100 ml to 10 mg/100 ml.
  • propellant gas-free solutions or suspensions can contain co-solvents and/or other excipients and/or preservative substances in addition to the active agents.
  • the preferred co-solvents are hydroxyl groups, alcohols, especially other polar groups comprising isopropyl alcohols and glycols.
  • the said excipients are substances which do not hold active agent characteristics such as tocopherols, vitamins, provitamins, surfactans.
  • the preservative agents which are used in order to prevent the contamination caused by pathogens are cetyl pyridinium chloride, benzalkonium chloride, benzoic acid or benzoates as known in the prior art.
  • the medicament of the present invention comprising carmoterol and fluticasone and/or pharmaceutically acceptable derivatives thereof is preferably administered in dry powder form and dry powder inhalation devices are used for delivery of the medicament of the present invention.
  • the present invention provides delivery of the medicament comprising carmoterol and fluticasone and/or pharmaceutically acceptable derivatives thereof by dry powder inhalers.
  • tsaid dry powder formulations comprise pharmaceutically acceptable excipients in addition to the active agents.
  • excipients can be selected from monosaccharides (glucose, etc.), disaccharides (lactose, saccharose, maltose, etc.), oligosaccharides and polysaccharides (dextran, etc.), polyalcohols (sorbitol, mannitol, xylitol, etc.), salts (sodium chloride, calcium carbonate, etc.) or a combination thereof.
  • lactose is used as an excipient in the medicament of the present invention.
  • the amount of pharmaceutically acceptable excipient is in the range of 0 to 50 mg, for example in the range of 1 mg to 48 mg, 1 mg to 47 mg, 1 mg to 42 mg, 1 mg to 40 mg, 1 mg to 38 mg, 1 mg to 35 mg, 1 mg to 32 mg, 1 mg to 30 mg, 1 mg to 28 mg, 1 mg to 25 mg , 1 mg to 23 mg, 2 mg to 48 mg, 2 mg to 47 mg, 2 mg to 42 mg, 2 mg to 40 mg, 2 mg to 38 mg, 2 mg to 35 mg, 2 mg to 32 mg, 2 mg to 30 mg, 2 mg to 28 mg, 2 mg to 25 mg , 2 mg to 23 mg, 2 mg to 20 mg, 3 mg to 48 mg, 3 mg to 47 mg, 3 mg to 42 mg, 3 mg to 40 mg, 3 mg to 38 mg, 3 mg to 35 mg, 3 mg to 32 mg, 3 mg to 30 mg, 3 mg to 28 mg, 3 mg to 25 mg.
  • the amount of the pharmaceutically acceptable excipient is most preferably in the range of 3 mg to 20 mg
  • the medicament comprising carmoterol and fluticasone and/or pharmaceutically acceptable derivatives thereof is delivered via a dry powder inhaler in which the medicament is stored in a peelable blister pack, reservoir or capsule for the treatment of patients with respiratory diseases.
  • inhalation devices designed to provide delivery of the dry powder medicament
  • a specific dose of the medicament in dry powder form is prepared for inhalation in response to each actuation of the device.
  • the medicament formulation containing more than one dose is stored in the reservoir of the device and one dose of dry powder medicament is inhaled by the patient each time the device is triggered.
  • carmoterol and/or a pharmaceutically acceptable derivative thereof which is one of the active agents in said medicament comprising the combination of active agents, is selected from the pharmaceutically acceptable solvates, hydrates, enantiomers or diastereomers, racemates, the free base, organic salts, inorganic salts, esters, polymorphs, crystalline and amorphous forms of carmoterol and/or a combination thereof.
  • R,R diastereomer of the carmoterol is preferably used in the medicament of the present invention.
  • fluticasone and/or a pharmaceutically acceptable derivative thereof which is one of the active agents contained in said medicament the combination of active agents, is selected from the pharmaceutically acceptable solvates, hydrates, enantiomers or diastereomers, racemates, the free base, organic salts, inorganic salts, esters, polymorphs, crystalline forms and amorphous forms of fluticasone and/or a combination thereof.
  • Fluticasone propionate is preferably used in the medicament of the present invention.
  • the amount of carmoterol which is one of the active agents comprised in the said medicament containing the combination of carmoterol and fluticasone and/or pharmaceutically acceptable derivatives thereof, in the range of 0.01 ⁇ g, 0.05 ⁇ g, 0.1 ⁇ g, 0.2 ⁇ g, 0.3 ⁇ g, 0.4 ⁇ & 0.5 ⁇ g, 0.6 ⁇ g, 0.7 ⁇ 3 ⁇ 4 0.8 ⁇ g, 0.9 ⁇ g or 1 ⁇ g to 7 ⁇ & 8 ⁇ g, 9 ⁇ 10 ⁇ g, 12 ⁇ g, 15 ⁇ g, 17 ⁇ g, 20 ⁇ g, 22 ⁇ g, 25 ⁇ g or 30 ⁇ g, for example 0.01 ⁇ g to 30 ⁇ g, 0.01 ⁇ g to 27 ⁇ g, 0.01 ⁇ g to 25 ⁇ g, 0.01 ⁇ g to 23 ⁇ g, 0.01 ⁇ g to 20 ⁇ g, 0.01 ⁇ g to 18 ⁇ g, 0.01 ⁇ g to 15 ⁇
  • the amount of fluticasone or a pharmaceutically acceptable derivative thereof included in the medicament composition comprising carmoterol and fluticasone and/or pharmaceutically acceptable derivatives thereof is in the range of 1 ⁇ g, 5 ⁇ g, 10 ⁇ & 15 ⁇ g, 25 ⁇ g or 30 ⁇ to 400 ⁇ g, 450 ⁇ g, 500 ⁇ g, 550 ⁇ g, 600 ⁇ ⁇ , 650 ⁇ g, 700 %, 750 ⁇ g, 800 ⁇ g, 850 ⁇ g, 900 ⁇ g, 950 ⁇ g or 1000 ⁇ g for example 1 ⁇ g to 1000 ⁇ g, 1 ⁇ g to 950 ⁇ g, 1 ⁇ g to 900 ⁇ g, 1 ⁇ g to 850 ⁇ g, 1 ⁇ g to 800 ⁇ , 1 ⁇ g to 750 ⁇ & 1 ⁇ g to 700 ⁇ g, 1 g to 650 ⁇ g, 1 ⁇ g to 600 ⁇ g, 1 ⁇ g to 550 ⁇
  • the medicament composition in accordance with the present invention is preferably in the form of micronized dry powder particles.
  • the active agents present in said medicament composition have average particle size of 1 ⁇ to 20 ⁇ , preferably from 1 ⁇ to 10 ⁇ , most preferably 1 ⁇ to 6 ⁇ .
  • Lactose particles present in said medicament composition as an excipient has average particle size of not more than 300 ⁇ , preferably not more than 250 ⁇ .
  • the lactose particles in the medicament composition can be found in more than one fraction with different average particle size.
  • the pharmaceutical composition comprising carmoterol and fluticasone and/or pharmaceutically acceptable derivatives thereof may additionally comprise one or more substances selected from the group comprising mast cell stabilizer, anticholinergic, adrenergic agonist, glucocorticosteroid, xanthine, anti-leukotriene, PDE IV inhibitor, EGFR inhibitor, anti-allergic, anti-inflammatory, antihistaminic and anti-muscarinic agents.
  • the pharmaceutical composition comprising carmoterol and fluticasone and/or pharmaceutically acceptable derivatives thereof can additionally comprise one or more substances selected from the group consisting of mast cell stabilizers such as cromoglycate, nedocromil; anticholinergics such as tiotropium, ipratropium, glicopirronium, cromoglycate, oxytropium; ⁇ 2 - agonists such as formoterol, arformoterol, bambuterol, salmeterol, clenbuterol, salbutamol, fenoterol, terbutaline, carbuterol, pirbuterol; corticosteroids such as beclomethasone, budesonide, fluticasone, ciclesonide; xanthines such as doxophylline, theobromine, theophylline, aminophylline; anti-leukotrienes such as montelukast, pranlukast, zafir
  • the pharmaceutical composition comprising carmoterol and fluticasone and/or pharmaceutically acceptable derivatives thereof can additionally comprise cromoglycate and/or a pharmaceutically acceptable derivative thereof.
  • Cromoglycate derivatives mentioned in the invention comprise the pharmaceutically acceptable solvates, hydrates, enantiomers or diastereomers, racemates, the free base, organic salts, inorganic salts, esters, polymorphs, crystalline and amorphous forms of cromoglycate and/or a combination thereof.
  • Sodium cromoglycate is preferably used in the preparation of the medicament of the present invention.
  • the medicament comprising carmoterol and fluticasone and/or pharmaceutically acceptable derivatives thereof according to the present invention can be used in the treatment of many respiratory diseases, particularly in asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis.
  • these respiratory diseases can be, but not limited to, asthma at any phase, acute lung injury (ALI), acute respiratory distress syndrome (ARDS), exacerbation of airway hyperactivity, bronchiectasis, chronic obstructive pulmonary including emphysema and chronic bronchitis, respiratory diseases or lung diseases (COPD, COAD or COLD), pneumoconiosis, aluminosis, anthracosis, asbestosis, chalicosis, ptilosis, siderosis, silicosis, tabacosis, byssinosis.
  • This treatment can be prophylactic or symptomatic.
  • the composition of the present invention is especially used for symptomatic treatment of asthma and COPD.
  • composition pertaining to the present invention can be explained with, but not limited to, the examples given below.
  • the active agent carmoterol given in the following examples comprises all pharmaceutically acceptable racemates, enantiomers or diastereomers, salts, solvates, esters, hydrates and/or the free base, polymorphs, amorphous and crystalline forms thereof.
  • the active agent fluticasone given in the following examples comprises all pharmaceutically acceptable salts, solvates, esters, hydrates and/or enantiomers, polymorphs, amorphous and crystalline forms thereof.
  • Carmoterol or a pharmaceutically acceptable derivative thereof is preferably in the form of R,R-carmoterol.
  • the pharmaceutically acceptable excipient given in the following examples can optionally be added in a higher or a lower amount.
  • the capsule described in the following examples is made of gelatin; however, it can optionally be made of chitosan, starch and/or starch derivatives, cellulose and/or cellulose derivatives or synthetic polymers.
  • the active agent cromoglycate given in the following examples comprises all pharmaceutically acceptable racemates, enantiomers or diastereomers, solvates, esters, hydrates and/or the free base, polymorphs, amorphous and crystalline forms of cromoglycate.
  • a dry powder formulation suitable to be stored in blister packs so as to be used via a multi-dose inhaler comprises 1 part of carmoterol, 400 parts of fluticasone having an average particle size in the range of 1 to 5 ⁇ , and 10000 parts of lactose having a particle size below 300 ⁇ as an excipient all of which are micronized in an air jet mill.
  • the example can be repeated by replacing the amounts given in example 1 with the amounts given in the table below.
  • the dry powder formulation which is suitable to be stored in a gelatin capsule so as to be used via an inhaler comprises 1 part of carmoterol, 200 parts of fluticasone having an average particle size in the range of 1 to 5 ⁇ , and 5500 parts of lactose as an excipient having an average particle size below 300 ⁇ all of which were micronized in an air jet mill.
  • the example can be repeated by replacing the amounts given in the table below with the amounts given in example 20.
  • a dry powder formulation suitable to be stored in blisters so as to be used via a multiple dose inhaler comprises 2 parts of carmoterol, 200 parts of fluticasone and 10000 parts of sodium chromoglycate having an average particle size in the range of 1 to 5 ⁇ , and 10000 parts of lactose as an excipienthaving an average particle size below 300 ⁇ all of which were micronized in an air jet mill.
  • the dry powder formulation which is suitable to be stored in a gelatin capsule so as to be used via an inhaler comprises 2 parts of carmoterol, 200 parts of fluticasone and 10000 parts of sodium chromoglycate sodium having an average particle size in the range of 1 to 5 ⁇ , and 10000 parts of lactose as an excipient having an average particle size below 300 ⁇ all of which were micronized in an air jet mill.
  • An aerosol formulation developed to be used in a metered dose inhalator comprises 2 parts of carmoterol, 200 parts of fluticasone and excipients in a ratio of 97% by weight of the total formulation.

Abstract

La présente invention concerne une composition pharmaceutique comprenant du carmotérol et de la fluticasone et/ou des dérivés pharmaceutiquement acceptables de ceux-ci en tant que principes actifs, laquelle composition peut être utilisée pour traiter des maladies des voies respiratoires, en particulier, pour traiter l'asthme et une maladie pulmonaire obstructive chronique (MPOC). L'invention concerne également l'administration de cette composition pharmaceutique.
EP11720621A 2010-04-26 2011-04-25 Combinaison de carmotérol et de fluticasone utilisée pour le traitement de maladies respiratoires Withdrawn EP2563364A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR201003237 2010-04-26
PCT/TR2011/000113 WO2011136753A1 (fr) 2010-04-26 2011-04-25 Combinaison de carmotérol et de fluticasone utilisée pour le traitement de maladies respiratoires

Publications (1)

Publication Number Publication Date
EP2563364A1 true EP2563364A1 (fr) 2013-03-06

Family

ID=44120870

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11720621A Withdrawn EP2563364A1 (fr) 2010-04-26 2011-04-25 Combinaison de carmotérol et de fluticasone utilisée pour le traitement de maladies respiratoires

Country Status (2)

Country Link
EP (1) EP2563364A1 (fr)
WO (1) WO2011136753A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201105367A2 (tr) * 2011-06-02 2012-12-21 Bi̇lgi̇ç Mahmut Akış özellikleri geliştirilmiş bir kuru toz formülasyonu.
WO2013109218A1 (fr) * 2012-01-16 2013-07-25 Mahmut Bilgic Formulations en poudre sèche comprenant du carmotérol et de la ciclésonide
KR20150002774A (ko) * 2012-04-11 2015-01-07 시플라 리미티드 아르포르모테롤 및 플루티카손 푸로에이트를 포함하는 약학 조성물
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
EP2847207B1 (fr) 2012-05-08 2019-03-27 Nicox Ophthalmics, Inc. Nanocristaux du propionate de fluticasone
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH24267A (en) 1980-02-15 1990-05-29 Glaxo Group Ltd Androstane carbothioates and pharmaceutical compositions containing the same
GB8334494D0 (en) 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
EP1452179A1 (fr) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Nouveau combination d'un puissant agoniste beta 2 de longue duree et un corticosteroid
GB0507165D0 (en) * 2005-04-08 2005-05-18 Glaxo Group Ltd Novel crystalline pharmaceutical product
JP2009532339A (ja) * 2006-03-22 2009-09-10 スリーエム イノベイティブ プロパティズ カンパニー 新規製剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO2011136753A1 *

Also Published As

Publication number Publication date
WO2011136753A1 (fr) 2011-11-03

Similar Documents

Publication Publication Date Title
WO2011136754A1 (fr) Médicament mis au point pour le traitement de maladies respiratoires
CA2477885C (fr) Formulations hfa de beta 2-agonistes a action prolongee de derives de 2(1h)-qiunolinone
ES2309503T3 (es) Medicamento que comprende un agonista beta 2 de larga duracion, muy potente, en combinacion con otros ingredientes activos.
EP1531866A1 (fr) Produits et compositions pharmaceutiques comprenant des agents anticholinergiques specifiques, des agonistes beta-2 et des corticosteroides
IL143986A (en) Combinations of formotrol and tiotropium salt
JP2004500429A (ja) チオトロピウム及びロフレポニドを含む医薬用の組み合わせ
JP2004538241A (ja) チオトロピウムとプロピオン酸フルチカゾンを含む組合せ医薬
JP2010539182A (ja) 治療剤の新規組み合わせ
JP2014516062A (ja) ウメクリジニウム及びコルチコステロイドを含む組合せ
EP2563364A1 (fr) Combinaison de carmotérol et de fluticasone utilisée pour le traitement de maladies respiratoires
EP3142654A1 (fr) Combinaisons de bromure de tiotropium, de formotérol et de budésonide pour le traitement de la bronchopneumopathie chronique obstructive
WO2012030308A2 (fr) Formulation comprenant la cellobiose
WO2011136752A1 (fr) Composition pharmaceutique combinée comprenant du carmotérol et du ciclésonide pour le traitement de maladies respiratoires
EP2611447A2 (fr) Formulation comprenant le tiotropium et un inhibiteur des canaux calciques
EP2515845A1 (fr) Combinaison de poudres sèches de tiotropium, de formotérol et d'un dérivé d'acide cromoglycique
EP2515847A1 (fr) Poudre séche combinant tiotropium, mométasone et un dérivé d'acide cromoglicique
TW201605440A (zh) 阿地銨之新用途
EP2480287A2 (fr) Association de tiotropium sous forme de poudre sèche

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20121108

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20161201

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20200103